A pharmaceutical company that manufactures drugs to treat myeloma has donated a total of $10 million to the Myeloma Institute at the University of Arkansas for Medical Sciences, UAMS announced today at a press conference attended by several UAMS administrators and Gov. Asa Hutchinson.

Celgene Corp.’s gift will be divided in half: $5 million will create the Bart Barlogie Center for Molecular Diagnostics and the other $5 million for the Celgene Distinguished Endowed Chair in Molecular Therapeutics. 

Advertisement

Barlogie led the UAMS myeloma program from 1989 to 2014. He now focuses on clinical care and research with an emphasis on curing high-risk melanoma. He was succeeded by Dr. Gareth Morgan.

Barlogie has been involved in drug trials with Celgene for several years and is a consultant to the company.

Advertisement

Also in attendance at the announcement were Myeloma Institute Board Chair Carol Ammon, of Wilmington; Myeloma Institute Board Member Stuart Cobb, who spoke about her experience as a Myeloma Institute patient; UAMS Chancellor Dr Dan Rahn, Morgan and Barlogie.

 

Advertisement

Help to Keep Great Journalism Alive in Arkansas

Join the fight for truth and become a subscriber of the Arkansas Times. We've been battling powerful forces for 50 years through our tough, determined, and feisty journalism. With over 63,000 Facebook followers, 58,000 Twitter followers, 35,000 Arkansas blog followers, and 70,000 daily email blasts, our readers value great journalism. But we need your help to do even more. By subscribing and supporting our efforts, you'll not only have access to all of our articles, but you'll also be helping us hire more writers to expand our coverage. Together, we can continue to hold the powerful accountable and bring important stories to light. Subscribe now or donate for as little as $1 and be a part of the Arkansas Times community.

Previous article Mark Pryor heads in the direction of the lobby Next article House approves bill to force guns on college campuses